BR112022002520A2 - Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer - Google Patents

Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer

Info

Publication number
BR112022002520A2
BR112022002520A2 BR112022002520A BR112022002520A BR112022002520A2 BR 112022002520 A2 BR112022002520 A2 BR 112022002520A2 BR 112022002520 A BR112022002520 A BR 112022002520A BR 112022002520 A BR112022002520 A BR 112022002520A BR 112022002520 A2 BR112022002520 A2 BR 112022002520A2
Authority
BR
Brazil
Prior art keywords
nsd2
purine
piperidinyl
amines
inhibitors
Prior art date
Application number
BR112022002520A
Other languages
English (en)
Portuguese (pt)
Inventor
Ce Wang
Counde Oyang
Guoliang Xun
Haibing Deng
Haiqiang Zeng
Jinbiao Liu
Qitao Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112022002520A2 publication Critical patent/BR112022002520A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022002520A 2019-08-14 2020-08-12 Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer BR112022002520A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/100542 WO2021026803A1 (en) 2019-08-14 2019-08-14 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
PCT/IB2020/057602 WO2021028854A1 (en) 2019-08-14 2020-08-12 Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents

Publications (1)

Publication Number Publication Date
BR112022002520A2 true BR112022002520A2 (pt) 2022-05-10

Family

ID=72145436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002520A BR112022002520A2 (pt) 2019-08-14 2020-08-12 Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer

Country Status (20)

Country Link
US (3) US11420970B1 (https=)
EP (2) EP4013755B1 (https=)
JP (2) JP7638960B2 (https=)
KR (1) KR102946008B1 (https=)
CN (1) CN114585622B (https=)
AU (1) AU2020328919A1 (https=)
BR (1) BR112022002520A2 (https=)
CO (1) CO2022002804A2 (https=)
DK (1) DK4013755T3 (https=)
EC (1) ECSP22019360A (https=)
ES (1) ES3023540T3 (https=)
FI (1) FI4013755T3 (https=)
IL (2) IL289754B2 (https=)
MX (1) MX2022001784A (https=)
MY (1) MY209614A (https=)
PH (1) PH12022550343A1 (https=)
PL (1) PL4013755T3 (https=)
PT (1) PT4013755T (https=)
WO (2) WO2021026803A1 (https=)
ZA (1) ZA202200519B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
DK4013756T3 (da) * 2019-09-20 2024-05-27 Novartis Ag MLL1-inhibitorer og anticancermidler
JP2025504379A (ja) * 2022-01-05 2025-02-12 ケイ３６・セラピューティクス・インコーポレイテッド 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用
IL314895A (en) * 2022-02-16 2024-10-01 Duke Street Bio Ltd Pharmaceutical compound
WO2023225150A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) * 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
AU2023273656A1 (en) * 2022-05-18 2024-11-28 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) * 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230038A1 (en) * 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
US20250361235A1 (en) * 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2024073283A1 (en) * 2022-09-26 2024-04-04 Board Of Regents, The University Of Texas System Heterocycles as modulators of nsd activity
JP2025530501A (ja) * 2022-09-26 2025-09-11 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｓｄ活性の修飾物質としての複素環
KR20250129690A (ko) * 2022-12-12 2025-08-29 케이36 테라퓨틱스, 인크. 피페리딘일-메틸-푸린 아민을 함유하는 약학적 조성물과 질환 및 병태 치료에서 이의 용도
WO2025106786A1 (en) * 2023-11-17 2025-05-22 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117720550A (zh) * 2023-12-14 2024-03-19 深圳市华先医药科技有限公司 (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025147514A1 (en) * 2024-01-02 2025-07-10 K36 Therapeutics, Inc. Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer
CN118459395A (zh) * 2024-05-10 2024-08-09 南通大学 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US7332486B2 (en) * 2002-08-08 2008-02-19 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
MXPA05003193A (es) * 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
JP2004137157A (ja) * 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
JP5694345B2 (ja) * 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2019196918A1 (zh) 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
CN109223794B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN108853110B (zh) 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
WO2021026803A1 (en) * 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
JP2025504379A (ja) 2022-01-05 2025-02-12 ケイ３６・セラピューティクス・インコーポレイテッド 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用
AU2023273656A1 (en) 2022-05-18 2024-11-28 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
KR20220047330A (ko) 2022-04-15
US20230002388A1 (en) 2023-01-05
AU2020328919A1 (en) 2022-02-17
EP4013755A1 (en) 2022-06-22
EP4013755B1 (en) 2025-01-08
IL289754A (en) 2022-03-01
CN114585622B (zh) 2024-08-09
KR102946008B1 (ko) 2026-04-01
CN114585622A (zh) 2022-06-03
CA3144542A1 (en) 2021-02-18
US11420970B1 (en) 2022-08-23
IL320143A (en) 2025-06-01
DK4013755T3 (da) 2025-03-31
ECSP22019360A (es) 2022-04-29
MY209614A (en) 2025-07-24
IL289754B2 (en) 2025-09-01
PH12022550343A1 (en) 2023-03-13
WO2021026803A1 (en) 2021-02-18
US12312353B2 (en) 2025-05-27
JP2022544946A (ja) 2022-10-24
JP2025081505A (ja) 2025-05-27
MX2022001784A (es) 2022-04-18
CO2022002804A2 (es) 2022-04-08
ES3023540T3 (en) 2025-06-02
JP7638960B2 (ja) 2025-03-04
FI4013755T3 (fi) 2025-04-02
PL4013755T3 (pl) 2025-05-12
WO2021028854A1 (en) 2021-02-18
IL289754B1 (en) 2025-05-01
PT4013755T (pt) 2025-05-02
US20250276971A1 (en) 2025-09-04
EP4559915A1 (en) 2025-05-28
ZA202200519B (en) 2024-08-28

Similar Documents

Publication Publication Date Title
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BR112022010383A2 (pt) Compostos tricíclicos substituídos
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112022012641A2 (pt) Compostos tricíclicos substituídos
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
SA521430853B1 (ar) Nlrp3 مثبطات جسيم التهابي
SA521431048B1 (ar) مركبات بيروليدين
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
BR112016029846A2 (pt) ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo?
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
BR112016024571A2 (pt) composto de 1,2,4-triazina dissubstituído
PH12022551523A1 (en) Cyclic compounds and methods of using same
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112021019817A2 (pt) Compostos de pirrol
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.
BR112023015425A2 (pt) Derivados de uracila como inibidores de trpa1
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
SA523440367B1 (ar) مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1
MX2024002131A (es) Inhibidores de la 17-beta-hidroxisteroide deshidrogenasa tipo 13 y metodos de uso de los mismos.